Compounds > oxybutynin

oxybutynin and atorvastatin

oxybutynin has been researched along with atorvastatin in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Aboud, HM; Ali, AA; Hassan, AH; Johnston, TP; Mahmoud, MO1
Anjani, QK; Donnelly, RF; Elliott, C; Greer, B; McCarthy, HO; Naser, YA; Peng, K; Tekko, IA; Vora, LK1

Reviews

1 review(s) available for oxybutynin and atorvastatin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

4 other study(ies) available for oxybutynin and atorvastatin

ArticleYear
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Recent changes to FDA-approved labeling.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2004, Sep-01, Volume: 61, Issue:17

    Topics: Acetamides; Aminoquinolines; Atazanavir Sulfate; Atorvastatin; Botulinum Toxins, Type A; Dosage Forms; Drug Labeling; Epoetin Alfa; Erythropoietin; Heptanoic Acids; Humans; Imiquimod; Insulin; Insulin Lispro; Mandelic Acids; Oligopeptides; Oseltamivir; Pyridines; Pyrroles; Recombinant Proteins; United States; United States Food and Drug Administration

2004
Transdermal delivery of atorvastatin calcium from novel nanovesicular systems using polyethylene glycol fatty acid esters: Ameliorated effect without liver toxicity in poloxamer 407-induced hyperlipidemic rats.
    Journal of controlled release : official journal of the Controlled Release Society, 2017, 05-28, Volume: 254

    Topics: Administration, Cutaneous; Animals; Atorvastatin; Biological Availability; Chemistry, Pharmaceutical; Cholesterol; Drug Delivery Systems; Drug Liberation; Esters; Fatty Acids; Glycerides; Glycerol; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lecithins; Liver; Male; Nanocapsules; Particle Size; Permeability; Poloxamer; Polyethylene Glycols; Polysorbates; Rats, Wistar; Skin Absorption; Transdermal Patch

2017
Hydrogel-forming microarray patches with solid dispersion reservoirs for transdermal long-acting microdepot delivery of a hydrophobic drug.
    Journal of controlled release : official journal of the Controlled Release Society, 2023, Volume: 356

    Topics: Administration, Cutaneous; Animals; Atorvastatin; Drug Delivery Systems; Hydrogels; Rats; Rats, Sprague-Dawley; Skin; Skin Absorption; Transdermal Patch

2023